National Pharmaceutical Council转发了
Does Institute for Clinical and Economic Review (ICER)'s shared savings approach need revisiting? The findings of a National Pharmaceutical Council study published in Value in Health suggest that this unconventional method further reduces ICER's recommended prices for certain treatments aimed at rare, severe, and pediatric diseases. What do you think? https://lnkd.in/eQC6av8C
Smadar Bustan, PhD
3 天前
This article reflects precisely what I have observed on the ground. Unfortunately, based on my experience with trials in rare diseases and pediatric oncology, funding is extremely limited due to cost-effectiveness concerns, and we often have to rely on philanthropy. Additionally, many pharmaceutical investors—though not all—are hesitant to invest in pediatric clinical studies, as they are often seen as lacking significant financial return.
Health Policy Regulatory and Legislative Expertise; Market Innovator
2 天前What I am thinking is that many people are unfocused as to the pain employer based insurance is experiencing. The model is unraveling, so is the unsubsidized portion of the exchanges. High claim costs above a million are a large part of it.